ClinicalTrials.gg
RecruitingNCT06381609PEERSIADUpdated Oct 21, 2026

Peer Support in Alcohol Dependence

An interventional study of Quality life questionnaire AQoLS and Quality life questionnaire Euroqol EQ-5D-5L in Alcohol Use Disorder, sponsored by Hospices Civils de Lyon. Recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 21, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
626
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Alcoholism with a site in France — 24 open to participants now, 25 under way, 1 of them phase 3. Alcoholism · France.

Planned enrollment
4th of 58
626 · median 153
Started
2026
with 7 others
No phase
42 of 94
15 open now
Primary completion
2030-04
later than 22 of 24 live
Registered
79th of 94
by date

Among the 94 studies in Alcoholism with a site in France, this one is the 4th largest by planned enrollment of the 58 interventional ones that give a count, is one of 8 that started in 2026, is one of 42 with no phase, reaches primary completion later than 22 of the 24 other live ones, and was the 79th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

24 of the 94 studies in Alcoholism with a site in France are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Alcoholism with a site in France, or all of them as a file.
02

Study summary

Alcohol use disorder (AUD) affects between 4% and 6% of French adults, and requires appropriate medical treatment.

However, 20-40% of patients with AUD are lost to follow-up at an early stage. Consequently, it is important for addiction departments to implement and evaluate innovative tools and interventions, including the involvement of peer support, to help patients remain in care, and to assess whether peer support has a positive impact on their clinical outcome.

Addiction peer support specialists (APSSs) are individuals who have personally experienced addiction, and who have decided to use their experience to assist other people going through a similar situation, after completing a specific official graduation.

Compared to other caregivers, APSSs may induce in patients a sense of identification which could improve the patient motivation to engage and remain in care.

This is the main hypothesis and the main scientific objective of the PEERSIAD study, which will aim to confirm that accompanying patients with AUD using APSSs after alcohol detoxification, reduces the rate of lost-to-follow-up and improves the overall clinical outcome.

03

Conditions studied

  • Alcohol Use Disorder

Keywords

  • Peer support
  • Addiction
  • Alcohol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18
  • Socially insured
  • Meeting criteria for alcohol use disorder (AUD)
  • Abstinent from alcohol and involved in supervised alcohol withdrawal for at least 5 days and no more than 21 days (outpatient or inpatient)
  • Starting a post-detoxification outpatient program

Exclusion criteria

Exclusion Criteria:

  • Other severe substance use disorder, i.e. criteria ≥ 6 (excluding tobacco)
  • Patient under protective measure (safeguard measure, guardianship) or deprived of liberty or in ordered care and hospitalization measures without consent.
  • Inability to communicate and express oneself orally in French, compromising the possibility of exchanges between the Peer support and the patient.
  • Psychiatric or cognitive comorbidities making inclusion impossible, at the investigator's discretion.
  • Individual accompaniment by a Peer support in the 15 days prior to inclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
626 participants (estimated)

Study arms

  • Experimental
    Peer support Group

    313 patients will be recruited over 3 years in the peer support group. Patients will be accompanied by an addiction peer support specialist, as part of an "add-on" follow-up compared with conventional follow-up (same management as in the control group).

    Behavioral: Quality life questionnaire AQoLS · Behavioral: Quality life questionnaire Euroqol EQ-5D-5L · Other: Peer support consultations

  • Active comparator
    Control Group

    313 patients will be recruited over 3 years in the control group. Patients will receive "as usual" outpatient abstinence-maintenance follow-up, with consultations of all kinds (medical, psychological, nursing, group, etc.)

    Behavioral: Quality life questionnaire AQoLS · Behavioral: Quality life questionnaire Euroqol EQ-5D-5L

Interventions

  • BehavioralQuality life questionnaire AQoLS

    Quality life questionnaire AQoLS will be completed by patients of both arms at inclusion, three and six months after inclusion

  • BehavioralQuality life questionnaire Euroqol EQ-5D-5L

    Quality life questionnaire Euroqol EQ-5D-5L will be completed by patients of both arms at inclusion, three and six months after inclusion

  • OtherPeer support consultations

    For patients included in the Peer support group, eight mandatory consultations with a peer support specialist will be performed between the inclusion visit and during the three following months. Patients can request additional consultations with the peer support specialist during the 6 first months of follow-up

06

What researchers measure

Primary outcomes

  1. Unplanned cessation of care at 6 months

    The unplanned cessation of care at 6 months, excluding consultations with an APSS, with no further contact in the following month, is defined as having had a last planned consultation that was not fulfilled between M0 and M6

    Time frame: At 6 months after inclusion

Secondary outcomes

  1. Number of unfulfilled consultations

    The number of unfulfilled consultations (scheduled consultations, excluding Peer Support consultations, without patient's visit with or without justification) over the 6-month study follow-up period, collected from the medical records of the addictology department.

    Time frame: 6 months after inclusion

  2. Euroqol-5D-5L questionnaire score

    The differential cost-utility ratio, in relation to the innovative strategy including a Peer Support, will be assessed using the Euroqol-5D-5L questionnaire (EQ-5D-5L).

    Time frame: At inclusion, 3 and 6 months after inclusion

  3. Difference in costs (in euros)

    An additional analysis will be carried out if the cost-utility ratio is positive: Difference in costs (in euros) for the payer (French compulsory health insurance) between a scenario in which the innovative management is implemented and disseminated in practice and on French territory, and a scenario in which usual follow-up is maintained.

    Time frame: At 1, 2 and 3 years after the beginning of implementation on French territory

  4. Number of AUD criteria according to Diagnostic and Statistical Manual of Mental Disorders (DSM-5)

    Time frame: At inclusion, 3 and 6 months after inclusion

  5. Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) score

    Time frame: At inclusion, 3 and 6 months after inclusion

  6. average number of standard drinks declared per week

    Time frame: At inclusion, 3 and 6 months after inclusion

  7. Alcohol Quality of Life Scale (AQoLS) score

    Changes in quality of life will be measured using the AQoLS

    Time frame: At inclusion, 3 and 6 months after inclusion

  8. State-Trait Anxiety Inventory (STAI-Y) score

    Changes in levels of anxiety will be measured using STAI-Y

    Time frame: At inclusion, 3 and 6 months after inclusion

  9. Montgomery-Åsberg Depression Rating Scale (MADRS) score

    Changes in levels of depression will be measured using MADRS

    Time frame: At inclusion, 3 and 6 months after inclusion

  10. Cannabis Use Disorders Identification Test - Revised (CUDIT-R) score

    Changes in the severity of cannabis use will be measured by the CUDIT-R score

    Time frame: At inclusion, 3 and 6 months after inclusion

  11. type of opioid use

    Time frame: At inclusion, 3 and 6 months after inclusion

  12. frequency of opioid use

    Time frame: At inclusion, 3 and 6 months after inclusion

  13. type of psychostimulant use

    Time frame: At inclusion, 3 and 6 months after inclusion

  14. frequency of psychostimulant use

    Time frame: At inclusion, 3 and 6 months after inclusion

  15. Fagerström test score

    Tobacco use will be measured by the Fagerström test

    Time frame: At inclusion, 3 and 6 months after inclusion

  16. Health Care Satisfaction Questionnaire (HCSQ) score

    Patient's satisfaction will be measured by HCSQ questionnaire

    Time frame: At 6 months after inclusion

  17. Number of hospitalisations

    Measurement of the number of hospitalisations related or not to the AUD and the ratio of total hospital days to number of hospital admissions (based on medical records and patient interviews)

    Time frame: At 6 months after inclusion

  18. Service organization description

    Time frame: Before setting up of the study

  19. Description of type of support and missions performed by Peer Support

    Time frame: After last visit of last patient (around 3,5 years after first inclusion)

  20. Acceptability of Intervention Measure (AIM) score

    AIM score measured in Peer Support and medical staff

    Time frame: After last visit of last patient (around 3,5 years after first inclusion)

  21. AIM score

    AIM score measured in patients

    Time frame: At 6 months after inclusion

  22. Adoption of intervention

    adoption of intervention will be assessed through semi-structured interviews and measurement of the number of patients followed-up versus the number of eligible patients, refusals to be accompanied by APSS, and premature discontinuation of follow-up

    Time frame: After last visit of last patient (around 3,5 years after first inclusion)

  23. Intervention fidelity

    intervention fidelity will be assessed by monitoring APSS activity indicators, describing deviations from the protocol and semi-structured interviews

    Time frame: After last visit of last patient (around 3,5 years after first inclusion)

07

Study locations

1 of 5 sites recruiting
  • CH Le Vinatier
    Bron, 69500, France
    Recruiting
  • Hôpital Beaujon
    Clichy, 92110, France
    Not yet recruiting
    • Delphine MOISAN, MD-PhD · Contactdelphine.moisan@aphp.fr · +33 1 40 87 58 82
    • Delphine MOISAN, MD-PhD · Principal investigator
  • GH Nord, Hospices Civils de Lyon
    Lyon, 69004, France
    Not yet recruiting
    • Benjamin ROLLAND, Professor · Contact
    • Benjamin ROLLAND, Professor · Principal investigator
    • François BAILLY, MD-PhD · Sub investigator
  • CHS St Anne
    Paris, 75014, France
    Not yet recruiting
    • Clément VANSTEENE, MD-PhD · Contact
    • Clément · Contact
    • VANSTEENE, MD-PhD · Principal investigator
  • Bichat Hospital
    Paris, 75018, France
    Not yet recruiting
    • Pierre-Alexis GEOFFROY, MD-PhD · Contactpierrealexis.geoffroy@aphp.fr · +33 1 40 25 82 60
    • Pierre-Alexis GEOFFROY, MD-PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2030, 42 months after the start.

Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 42 months is above that.

Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: start Oct 2024 → Oct 2026, primary completion Apr 2028 → Apr 2030 and completion Apr 2028 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 24, 2024
StartActual
Oct 19, 2026was Oct 2024
Primary completionEst.
Apr 19, 2030was Apr 2028
CompletionEst.
Apr 19, 2030was Apr 2028
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 21, 2026
Sites
5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
Show 5 sites
  • CH Le Vinatier · Bron, Franceno status→Recruiting
  • Hôpital Beaujon · Clichy, Franceno status→Not yet recruiting
  • GH Nord, Hospices Civils de Lyon · Lyon, Franceno status→Not yet recruiting
  • CHS St Anne · Paris, Franceno status→Not yet recruiting
  • Bichat Hospital · Paris, Franceno status→Not yet recruiting
Oct 21, 2026
Start date
Oct 1, 2024→Oct 19, 2026 (actual)
Oct 21, 2026
Primary completion
Apr 1, 2028→Apr 19, 2030
Oct 21, 2026
Study completion
Apr 1, 2028→Apr 19, 2030
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (4 now not yet recruiting, 1 now recruiting)
    Show 5 sites
    • CH Le Vinatier · Bron, Franceno status→Recruiting
    • Hôpital Beaujon · Clichy, Franceno status→Not yet recruiting
    • GH Nord, Hospices Civils de Lyon · Lyon, Franceno status→Not yet recruiting
    • CHS St Anne · Paris, Franceno status→Not yet recruiting
    • Bichat Hospital · Paris, Franceno status→Not yet recruiting
    Start date Oct 1, 2024→Oct 19, 2026 (now actual)
    Primary completion Apr 1, 2028→Apr 19, 2030
    Study completion Apr 1, 2028→Apr 19, 2030
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06381609
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Oct 19, 2026
Primary completion
Apr 19, 2030 (estimated)
Completion
Apr 19, 2030 (estimated)
Last update
Oct 21, 2026

Study contacts

Benjamin ROLLAND, Professor
Contact
Benjamin.ROLLAND@chu-lyon.fr
04 37 91 50 75 ext. +33
Nathalie Perreton
Contact
nathalie.perreton@chu-lyon.fr
04 27 85 63 04 ext. +33
Benjamin ROLLAND
principal investigator · Hopsices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion